RBC
RXRX icon

Roble Belko & Company’s Recursion Pharmaceuticals RXRX Stock Holding History

Roble Belko & Company’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-141
Closed -$1K – 513
2025
Q3 		$1K Hold
141
– – ﹤0.01% 406
2025
Q2 		$1K Hold
141
– – ﹤0.01% 390
2025
Q1 		$1K Hold
141
– – ﹤0.01% 376
2024
Q4 		$1K Buy
141
+125
+781% +$840 ﹤0.01% 352
2024
Q3 		$0 Buy
+16
New +$115 ﹤0.01% 393

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Roble Belko & Company's RXRX Position: Q4 2025 in Review

Roble Belko & Company sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 141 shares — an estimated $1K sold.

Roble Belko & Company first reported a position in RXRX in Q3 2024 and held it in 5 quarters. The position peaked at $1K in Q3 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Roble Belko & Company reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Roble Belko & Company sold 141 Recursion Pharmaceuticals shares in Q4 2025, an estimated $1K.
  • Roble Belko & Company first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • Roble Belko & Company's Recursion Pharmaceuticals position peaked at $1K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Roble Belko & Company's 13F filing for Q4 2025, filed 12 Jan 2026.